| pubmed-article:16353201 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16353201 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:16353201 | lifeskim:mentions | umls-concept:C0441833 | lld:lifeskim |
| pubmed-article:16353201 | lifeskim:mentions | umls-concept:C0278791 | lld:lifeskim |
| pubmed-article:16353201 | lifeskim:mentions | umls-concept:C0034897 | lld:lifeskim |
| pubmed-article:16353201 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:16353201 | lifeskim:mentions | umls-concept:C0040808 | lld:lifeskim |
| pubmed-article:16353201 | lifeskim:mentions | umls-concept:C0332293 | lld:lifeskim |
| pubmed-article:16353201 | lifeskim:mentions | umls-concept:C1514923 | lld:lifeskim |
| pubmed-article:16353201 | lifeskim:mentions | umls-concept:C1705294 | lld:lifeskim |
| pubmed-article:16353201 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:16353201 | pubmed:dateCreated | 2006-1-12 | lld:pubmed |
| pubmed-article:16353201 | pubmed:abstractText | Combining therapeutics with single-agent activity has improved treatment for patients with many malignancies. Debate continues about the impact of treatment on survival in patients with chronic lymphocytic leukemia (CLL). Purine analogues are the most active agents for treatment of patients with CLL. Recently, it was shown that a chemoimmunotherapy regimen combining fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) was very effective in treating patients with recurrent and/or refractory CLL. The objective of the current analysis was to determine whether improvements in treatment have had an impact on survival for patients with CLL. | lld:pubmed |
| pubmed-article:16353201 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16353201 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16353201 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:16353201 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16353201 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16353201 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16353201 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16353201 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16353201 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16353201 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16353201 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16353201 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:16353201 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:16353201 | pubmed:author | pubmed-author:FaderlStefanS | lld:pubmed |
| pubmed-article:16353201 | pubmed:author | pubmed-author:WangXuemeiX | lld:pubmed |
| pubmed-article:16353201 | pubmed:author | pubmed-author:LernerSusanS | lld:pubmed |
| pubmed-article:16353201 | pubmed:author | pubmed-author:KantarjianHag... | lld:pubmed |
| pubmed-article:16353201 | pubmed:author | pubmed-author:Garcia-Manero... | lld:pubmed |
| pubmed-article:16353201 | pubmed:author | pubmed-author:DoKim-AnhKA | lld:pubmed |
| pubmed-article:16353201 | pubmed:author | pubmed-author:ThomasDeborah... | lld:pubmed |
| pubmed-article:16353201 | pubmed:author | pubmed-author:CortesJorgeJ | lld:pubmed |
| pubmed-article:16353201 | pubmed:author | pubmed-author:KeatingMichae... | lld:pubmed |
| pubmed-article:16353201 | pubmed:author | pubmed-author:WierdaWilliam... | lld:pubmed |
| pubmed-article:16353201 | pubmed:author | pubmed-author:O'brienSusanS | lld:pubmed |
| pubmed-article:16353201 | pubmed:author | pubmed-author:FerrajoliAles... | lld:pubmed |
| pubmed-article:16353201 | pubmed:author | pubmed-author:GilesFrancisF | lld:pubmed |
| pubmed-article:16353201 | pubmed:author | pubmed-author:Ravandi-Kasha... | lld:pubmed |
| pubmed-article:16353201 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16353201 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:16353201 | pubmed:volume | 106 | lld:pubmed |
| pubmed-article:16353201 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16353201 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16353201 | pubmed:pagination | 337-45 | lld:pubmed |
| pubmed-article:16353201 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:16353201 | pubmed:meshHeading | pubmed-meshheading:16353201... | lld:pubmed |
| pubmed-article:16353201 | pubmed:meshHeading | pubmed-meshheading:16353201... | lld:pubmed |
| pubmed-article:16353201 | pubmed:meshHeading | pubmed-meshheading:16353201... | lld:pubmed |
| pubmed-article:16353201 | pubmed:meshHeading | pubmed-meshheading:16353201... | lld:pubmed |
| pubmed-article:16353201 | pubmed:meshHeading | pubmed-meshheading:16353201... | lld:pubmed |
| pubmed-article:16353201 | pubmed:meshHeading | pubmed-meshheading:16353201... | lld:pubmed |
| pubmed-article:16353201 | pubmed:meshHeading | pubmed-meshheading:16353201... | lld:pubmed |
| pubmed-article:16353201 | pubmed:meshHeading | pubmed-meshheading:16353201... | lld:pubmed |
| pubmed-article:16353201 | pubmed:meshHeading | pubmed-meshheading:16353201... | lld:pubmed |
| pubmed-article:16353201 | pubmed:meshHeading | pubmed-meshheading:16353201... | lld:pubmed |
| pubmed-article:16353201 | pubmed:meshHeading | pubmed-meshheading:16353201... | lld:pubmed |
| pubmed-article:16353201 | pubmed:meshHeading | pubmed-meshheading:16353201... | lld:pubmed |
| pubmed-article:16353201 | pubmed:meshHeading | pubmed-meshheading:16353201... | lld:pubmed |
| pubmed-article:16353201 | pubmed:meshHeading | pubmed-meshheading:16353201... | lld:pubmed |
| pubmed-article:16353201 | pubmed:meshHeading | pubmed-meshheading:16353201... | lld:pubmed |
| pubmed-article:16353201 | pubmed:meshHeading | pubmed-meshheading:16353201... | lld:pubmed |
| pubmed-article:16353201 | pubmed:meshHeading | pubmed-meshheading:16353201... | lld:pubmed |
| pubmed-article:16353201 | pubmed:meshHeading | pubmed-meshheading:16353201... | lld:pubmed |
| pubmed-article:16353201 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16353201 | pubmed:articleTitle | A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. | lld:pubmed |
| pubmed-article:16353201 | pubmed:affiliation | Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. wwierda@mdanderson.org | lld:pubmed |
| pubmed-article:16353201 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16353201 | pubmed:publicationType | Comparative Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16353201 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16353201 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16353201 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16353201 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16353201 | lld:pubmed |
